about
Cancer immunotherapy: the beginning of the end of cancer?Tumor cell lysates as immunogenic sources for cancer vaccine designCombination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivoDistinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.Investigations of the functional states of dendritic cells under different conditioned microenvironments by Fourier transformed infrared spectroscopy.Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine.Recent advances in the molecular design of synthetic vaccines.Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.Dendritic Immunotherapy Improvement for an Optimal Control Murine Model.Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma.λ-Carrageenan improves the antitumor effect of dendritic cellbased vaccine.Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.Cancer immunotherapy: dendritic-cell vaccines on the move.Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
P2860
Q26752277-5ED61BFC-B5C3-4FD8-AF0C-7083ED7926B6Q28083469-98F245F4-DE48-4AB6-AFB1-2A0E88AD8994Q33688619-A90B7391-C497-4BD4-A84C-886A2F99A510Q33820274-94E5916C-369B-49C6-9CEF-C55396A987E4Q33850483-0A570698-C97B-4678-87D5-7DC7F5229E50Q36371484-00F9882E-B343-4BC4-8C21-FFE5A815DAD4Q37501316-24D1340E-9557-49F8-987D-B04B87037C10Q37686631-6C041237-F0ED-4F4A-B66A-EA77D4583406Q38639938-F49E0C16-9DE6-4F0C-91C1-134997DF57D6Q38864816-C6CDB092-9887-4B3C-BA38-5D18F520DE75Q40044826-D1CD512C-1D57-4533-8974-157A63A6EF02Q41062063-12B9D1BB-58F6-4DA7-B9A8-0D6693D33A51Q41853661-5539CE69-C966-453F-909D-399A737944AEQ48467671-7B5B4542-B445-4843-B800-F8ACF746A8E5Q52571242-0B08E3D9-32A7-4CBF-972A-97F7A0734D9AQ52959842-38636AE2-1C87-47BE-9E16-E0435D11EB75Q58797496-963F20D8-C95B-4072-ABFB-88E64076945B
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Dendritic cell immunotherapy.
@en
Dendritic cell immunotherapy.
@nl
type
label
Dendritic cell immunotherapy.
@en
Dendritic cell immunotherapy.
@nl
prefLabel
Dendritic cell immunotherapy.
@en
Dendritic cell immunotherapy.
@nl
P2860
P356
P1476
Dendritic cell immunotherapy.
@en
P2093
Nina Bhardwaj
Rachel Lubong Sabado
P2860
P356
10.1111/NYAS.12125
P407
P577
2013-05-01T00:00:00Z